CURE

ETFS S&P Biotech ETF

ASX Code: CURE

ETFS S&P Biotech ETF (ASX Code: CURE) offers investors exposure to U.S. healthcare biotechnology companies. These companies are engaged in the research, development and manufacturing of products based on genetic analysis and genetic engineering. Examples include the development of immunotherapy treatments and vaccines to treat human diseases.


About CURE

CURE aims to provide investors with a return that, before fees and expenses, tracks the performance of the S&P Biotechnology Select Industry Index. CURE uses a full-replication strategy to track the index, meaning that it holds all of the shares that make up the index. It is equal weighted, meaning each holding makes up the same portion of the portfolio and therefore contributes equally to overall performance.

To be eligible for inclusion in the index, companies must be part of the biotechnology sub-industry of the U.S. healthcare sector and meet minimum market capitalisation and liquidity requirements.

Why consider CURE

1

Simple, low cost exposure to the biotechnology sub-industry.

2

Access to the U.S. biotechnology market benefitting from the FDA drug approval and U.S. patent system.

3

Exposure to medical advances and potential mergers & acquisitions.

FAQs

What is biotechnology?

Biotechnology includes companies primarily engaged in the research, development, manufacturing and/or marketing of products based on genetic analysis and genetic engineering. It includes companies specialising in protein-based therapeutics to treat human diseases. It excludes companies manufacturing products using biotechnology but without a healthcare application. Biotechnology is a sub-industry of the healthcare sector.

How does biotechnology differ from healthcare?

Biotechnology is a sub-industry within the Healthcare sector.

The Healthcare sector refers to all those industries involved in providing goods and services to manage the health needs of individuals and populations. There are two main groupings within the healthcare sector according to the Global Industry Classification Standards (GICS) including:

  1. Healthcare equipment and services

  2. Pharmaceuticals, biotechnology, and Life Sciences.

How are companies in CURE weighted?

Companies in CURE are equally weighted (subject to liquidity constraints), meaning each holding makes up the same portion of the portfolio at each quarterly rebalance and therefore contributes equally to overall performance.

The choice of an equal weighting scheme provides investors exposure to the overall sector and allows all stocks to contribute equally to returns. Large-cap stocks do not dominate as they do where holdings are weighted by market capitalisation.

Why use CURE for biotechnology exposure?

While biotechnology can be a lucrative space, it can also be high risk. The drug development process is very lengthy with high failure rates and it is an area that is sensitive to government policy. Using an ETF like CURE not only spreads the risk over many biotechnology companies but reduces the single stock risk further by using an equal weight method.

CURE enables investors to access the growth in the U.S. biotechnology sector, without having to pick individual winners.

How can you use CURE in a portfolio?

CURE may be used as a tool for expressing long-term strategic or short-term tactical views on the biotechnology sub-industry.

CURE can also aid portfolio diversification via investment in a sector that is underrepresented in the Australian market.

Product Information

NAV Information
NAV/Unit (A$)61.6202
Date (NAV)07 May 2021
Currency (NAV)AUD
Shares outstanding741,947
AUM (A$)45,718,915.09
Product Information
Fund inception date08 Nov 2018
Management Costs (% p.a.)0.45
Distribution FrequencyAnnually
Currency HedgedNo
DomicileAustralia
Legal FormManaged Investment Scheme
SMSF EligibleYes

Trading Information

Symbols and Trading Hours
ASX CodeCURE
Bloomberg CodeCURE AU Equity
ISINAU0000028110
SEDOLBGYB2K4
IRESSCURE.AXW
Trading hours10:00AM – 4:00PM
Trade Online

Management & Administration

IssuerETFS Management (AUS) Limited
CustodianJPMorgan Chase Bank N.A. (Sydney Branch)
RegistrarComputershare Investor Services (Jersey) Ltd

Benchmark Information

BenchmarkS&P Biotechnology Select Industry Index
ProviderS&P Indices
TickerSPSIBIN

Allocation

Performance

Distributions

Recent Distribution
Announcement date24 Jun 2020
Ex-date30 Jun 2020
Record date1 Jul 2020
Payment date15 Jul 2020
Distribution per unit
(A$ cents)
675.621567
12-month yield10.96%
12-month franking level0.00%
Ex-date
Record date
Payment date
Distribution (A$ cents)
Franking level
30 Jun 202001 Jul 202015 Jul 2020675.6215670.0000%
28 Jun 201901 Jul 201915 Jul 2019117.3883500.0000%

Announcements

There are no announcements to display.

Resources

Videos

Biotech vs healthcare: how to play it in the ETF space

Webinar: Investing in Modern Healthcare with Biotechnology

1 Minute ETFs: ETFS S&P Biotech ETF (ASX Code: CURE)

Webinar: Invest in the essential - healthcare and biotechnology